[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2007132207A3 - Process for cross-linking moieties - Google Patents

Process for cross-linking moieties Download PDF

Info

Publication number
WO2007132207A3
WO2007132207A3 PCT/GB2007/001745 GB2007001745W WO2007132207A3 WO 2007132207 A3 WO2007132207 A3 WO 2007132207A3 GB 2007001745 W GB2007001745 W GB 2007001745W WO 2007132207 A3 WO2007132207 A3 WO 2007132207A3
Authority
WO
WIPO (PCT)
Prior art keywords
cross
linking moieties
moiety
linking
linker
Prior art date
Application number
PCT/GB2007/001745
Other languages
French (fr)
Other versions
WO2007132207A2 (en
Inventor
Graham Mock
Original Assignee
Graham Mock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Graham Mock filed Critical Graham Mock
Publication of WO2007132207A2 publication Critical patent/WO2007132207A2/en
Publication of WO2007132207A3 publication Critical patent/WO2007132207A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/28—Isothiocyanates having isothiocyanate groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6847—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a hormone or a hormone-releasing or -inhibiting factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C331/00—Derivatives of thiocyanic acid or of isothiocyanic acid
    • C07C331/16—Isothiocyanates
    • C07C331/30—Isothiocyanates containing at least two isothiocyanate groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a process for linking a first moiety with a linker and to cross-linking a first moiety such as a nucleic acid or protein with a second moiety such as an antibody or enzyme. In preferred embodiments of the invention, the linker is diisothiocyanatostilbenedisulphonic acid (DIDS) or a dimer thereof.
PCT/GB2007/001745 2006-05-11 2007-05-11 Process for cross-linking moieties WO2007132207A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0609370.2A GB0609370D0 (en) 2006-05-11 2006-05-11 Process for cross-linking macromolecules
GB0609370.2 2006-05-11

Publications (2)

Publication Number Publication Date
WO2007132207A2 WO2007132207A2 (en) 2007-11-22
WO2007132207A3 true WO2007132207A3 (en) 2008-08-21

Family

ID=36637328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/001745 WO2007132207A2 (en) 2006-05-11 2007-05-11 Process for cross-linking moieties

Country Status (2)

Country Link
GB (2) GB0609370D0 (en)
WO (1) WO2007132207A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201615466D0 (en) * 2016-09-12 2016-10-26 Gfc Diagnostics Ltd Method for detecting bacteria

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0398024A1 (en) * 1989-04-19 1990-11-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Conjugates for tumor localization and/or tumortherapy
EP0584794A2 (en) * 1992-08-25 1994-03-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Electrobiochemical analytical method and electrodes
US5532129A (en) * 1991-11-07 1996-07-02 Enterprise Partners Ii, L.P. Self-organizing molecular photonic structures based on chromophore- and fluorophore-containing polynucleotides and methods of their use
US6241863B1 (en) * 1998-04-27 2001-06-05 Harold G. Monbouquette Amperometric biosensors based on redox enzymes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4007000B2 (en) * 2001-12-25 2007-11-14 富士ゼロックス株式会社 Conductive organic polymer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0398024A1 (en) * 1989-04-19 1990-11-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Conjugates for tumor localization and/or tumortherapy
US5532129A (en) * 1991-11-07 1996-07-02 Enterprise Partners Ii, L.P. Self-organizing molecular photonic structures based on chromophore- and fluorophore-containing polynucleotides and methods of their use
EP0584794A2 (en) * 1992-08-25 1994-03-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Electrobiochemical analytical method and electrodes
US6241863B1 (en) * 1998-04-27 2001-06-05 Harold G. Monbouquette Amperometric biosensors based on redox enzymes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUA S. ET AL.: "Lys515-Lys492 Cross-linking by DIDS Interferes with substrate Utilization by the Sarcoplasmic reticulum ATPase", BIOPHYSICAL JOURNAL, vol. 73, 1997, pages 2149 - 2155, XP007904540 *
KAVANAUGH ET AL.: "Affinity labeling of hemoglobin with 4,4'-Diisothiocyanostilbene-2,2'-disulfonate: covalent cross-linking in the 2, 3-diphosphoglycerate binding site", BIOCHEMISTRY, vol. 27, 1988, pages 1804 - 1808, XP007904541 *

Also Published As

Publication number Publication date
GB2438088A (en) 2007-11-14
GB2438088B (en) 2010-04-28
WO2007132207A2 (en) 2007-11-22
GB0609370D0 (en) 2006-06-21
GB0709127D0 (en) 2007-06-20

Similar Documents

Publication Publication Date Title
WO2006105361A3 (en) Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
WO2009105670A3 (en) Substrates for multiplexed assays and uses thereof
AU2009209251A8 (en) Stabilized Angiopoietin-2 antibodies and uses thereof
WO2008098100A3 (en) Detection of molecule proximity
WO2007147159A3 (en) Functional nucleic acid ligands to fluorescent proteins
WO2007041689A3 (en) Methods of site-specific labeling of molecules and molecules produced thereby
WO2005059509A3 (en) Biosensors for detecting macromolecules and other analytes
WO2006131928A8 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2009019007A3 (en) Sdf-1 binding nucleic acids and the use thereof
WO2007115837A3 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
WO2009073201A3 (en) Alternate labeling strategies for single molecule sequencing
WO2007120265A3 (en) Coded molecules for detecting target analytes
WO2005017205A3 (en) Nucleic acid mapping using linear analysis
WO2010111686A3 (en) Labeled enzyme compositions, methods & systems
WO2007019492A3 (en) Methods for detection of a nucleic acid by sequential amplification
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2007039903A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2006086669A3 (en) Aptamer regulated nucleic acids and uses thereof
WO2009079212A3 (en) Linked peptide fluorogenic biosensors
WO2007008583A3 (en) Improved protein expression comparison assay results and applications
WO2007067983A3 (en) Sulfotyrosine specific antibodies and uses therefor
WO2008034622A3 (en) A method of detecting and/or quantifying expression of a target protein candidate in a cell, and a method of identifying a target protein of a small molecule modulator
UA95779C2 (en) Adhesive composition, process for the preparation thereof, combination based on a glue composition, method of gluing and product using adhesive composition
WO2009117726A3 (en) High-sensitive fluorescent energy transfer assay using fluorescent amino acids and fluoresent proteins
WO2005018552A3 (en) Heparin binding proteins: sensors for heparin detection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07732770

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07732770

Country of ref document: EP

Kind code of ref document: A2